Laura Prendergast
Stock Analyst at Raymond James
(n/a)
# 4,412
Out of 4,835 analysts
9
Total ratings
12.5%
Success rate
-34.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Laura Prendergast
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ERAS Erasca | Initiates: Outperform | $5 | $1.29 | +289.11% | 1 | Mar 26, 2025 | |
| THRD Third Harmonic Bio | Downgrades: Market Perform | n/a | $5.18 | - | 2 | Feb 11, 2025 | |
| MURA Mural Oncology | Initiates: Strong Buy | $18 | $2.65 | +579.25% | 1 | Oct 4, 2024 | |
| NKTX Nkarta | Upgrades: Strong Buy | $16 | $1.74 | +819.54% | 2 | Aug 14, 2024 | |
| BDTX Black Diamond Therapeutics | Initiates: Outperform | $20 | $1.95 | +925.64% | 1 | Jul 31, 2024 | |
| RVMD Revolution Medicines | Upgrades: Strong Buy | $36 → $48 | $39.54 | +21.40% | 2 | Apr 10, 2024 |
Erasca
Mar 26, 2025
Initiates: Outperform
Price Target: $5
Current: $1.29
Upside: +289.11%
Third Harmonic Bio
Feb 11, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $5.18
Upside: -
Mural Oncology
Oct 4, 2024
Initiates: Strong Buy
Price Target: $18
Current: $2.65
Upside: +579.25%
Nkarta
Aug 14, 2024
Upgrades: Strong Buy
Price Target: $16
Current: $1.74
Upside: +819.54%
Black Diamond Therapeutics
Jul 31, 2024
Initiates: Outperform
Price Target: $20
Current: $1.95
Upside: +925.64%
Revolution Medicines
Apr 10, 2024
Upgrades: Strong Buy
Price Target: $36 → $48
Current: $39.54
Upside: +21.40%